Expression of the capsid protein of Chikungunya virus in a baculovirus for serodiagnosis of Chikungunya disease

Cho, Byungki; Kim, Jungho; Cho, Jang-Eun; Jeon, Bo-Young; Park, Sun

doi:10.1016/j.jviromet.2008.07.031

Cited by 21 publications

(14 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When using complete CHIKV virion particles E2 glycoprotein was the only surface protein that reacted to the IgG of the patients' plasma collected during the early convalescent phase. We (Warter et al, 2011) and others have previously shown that other structural proteins including the E1 glycoprotein (Cho et al, 2008a; Kowalzik et al, 2008; Yap et al, 2010) and capsid (Cho et al, 2008b) are also detected to varying degrees by patients' IgGs from patients' samples collected at later time points. However, especially at the early phase of infection the E2 glycoprotein is apparently the only major target.…”

Section: Discussionmentioning

confidence: 71%

Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein

et al. 2012

View full text Add to dashboard Cite

Chikungunya virus (CHIKV) and related arboviruses have been responsible for large epidemic outbreaks with serious economic and social impact. The immune mechanisms, which control viral multiplication and dissemination, are not yet known. Here, we studied the antibody response against the CHIKV surface antigens in infected patients. With plasma samples obtained during the early convalescent phase, we showed that the naturally-acquired IgG response is dominated by IgG3 antibodies specific mostly for a single linear epitope ‘E2EP3’. E2EP3 is located at the N-terminus of the E2 glycoprotein and prominently exposed on the viral envelope. E2EP3-specific antibodies are neutralizing and their removal from the plasma reduced the CHIKV-specific antibody titer by up to 80%. Screening of E2EP3 across different patient cohorts and in non-human primates demonstrated the value of this epitope as a good serology detection marker for CHIKV infection already at an early stage. Mice vaccinated by E2EP3 peptides were protected against CHIKV with reduced viremia and joint inflammation, providing a pre-clinical basis for the design of effective vaccine against arthralgia-inducing CHIKV and other alphaviruses.

show abstract

Section: Discussionmentioning

confidence: 71%

Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein

et al. 2012

View full text Add to dashboard Cite

show abstract

“…[33] Commercial IgM assays using recombinant CHIKV protein in ELISA and ICTs have been developed. [34] However, most CHIKV patients present within a few days of symptom onset, before IgM is present. When some kits were tested in clinical settings, sensitivities for diagnosing acute CHIKV infection by IgM detection were just 4% to 22%, when compared with PCR.…”

Section: Problems With Current Diagnostic Modalities For Chikvmentioning

confidence: 99%

Laboratory diagnosis of chikungunya virus: Do we really need it?

Dash¹,

Mohanty²,

Padhi³

2011

Indian J Med Sci

View full text Add to dashboard Cite

Chikungunya (CHIK) fever is a re-emerging Aedes mosquito-transmitted viral disease caused by CHIK virus belonging to the Togaviridae family of genus Alphavirus. The disease is almost self-limiting, occurs with characteristic triad of sudden onset fever, rash and arthritis. During the recent outbreak CHIKV was also found to cause long-term arthralgia, severe neurological disease and even fatalities. Although there are no antiviral or vaccines available for CHIKV, still there are several advantages to diagnose the infection. The present article provides an overview of various diagnostic modalities available and its significance by searching PubMed MeSH terms "Chikungunya virus" and "Diagnosis" for recent articles. The gold standard of CHIKV diagnosis is culture, yet requires facilities and skills. Highly sensitive and specific PCR assays for CHIKV have been developed, but the reagents and equipment are costly for widespread use. Serological diagnosis by detecting IgM antibody is most widely used as it is relatively cheaper and easier to perform. Disadvantages of antibody testing are cross-reactivity with other alpha viruses, cannot differentiate between recent past and acute infection, and its sensitivity varies in clinical settings. When tested for diagnosing acute CHIKV disease, sensitivities were just 4 to 22% and after 1 week rose to more than 80%. As most acutely infected patients seek medical attention within the first few days of illness, the ideal test should detect RNA or antigen. Therefore, the more realistic aim would be to develop a reliable antigen detection assay that could be used in rural areas, where CHIKV infection often occurs.

show abstract

“…Reports indicate 85 % sensitivity and 100 % specificity [39] and 97 % accordance of indirect IgM detection ELISA using recombinant C protein when compared to a commercial kit [40]. Cho et al reported that using recombinant C protein in ICA gave 87.5 % sensitivity with 100 % specificity [38]. Goh et al first reported multiple applications of MAbs against the CHIKV C protein [53].…”

Section: Discussionmentioning

confidence: 99%

“…These antigens have been obtained from clinical specimens or cell culture. Recombinant C-, E1-and E2-protein-based indirect IgM ELISA and immunochromatography assays (ICA) exhibited sensitivity in the range of 77.5 %-100 % with 95 %-100 % specificity [38][39][40]. MAbs to E2 protein successfully detected CHIKV derived from mosquito and human cells in antigen-capture ELISA [41].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic potential of monoclonal antibodies against the capsid protein of chikungunya virus for detection of recent infection

et al. 2016

View full text Add to dashboard Cite

Chikungunya fever is self-limiting. However, neurological and hemorrhagic complications have been seen in recent outbreaks. The clinical manifestations of this disease are similar to those of dengue virus infection, indicating the need for differential diagnosis in areas such as India, which are endemic for both viruses. The aim of the present study was to develop monoclonal antibodies (MAbs) against Chikungunya virus (CHIKV) and assess their use in MAb-based IgM capture ELISA (MAC ELISA). The ELISA detects CHIKV-specific IgM antibodies, a marker of recent infection, in a patient's serum. One IgG1 and two IgM isotype hybrids were obtained. All of the subclones derived from the IgG1 hybrid recognized the C protein of CHIKV. The anti-C MAb ClVE4/D9 was the most promising as a detector antibody in MAC ELISA (C-MAb ELISA) yielding higher positive-to-negative (P/N) ratios. When compared with the CHIKV MAC ELISA kit developed by the National Institute of Virology (NIV), Pune (NIV MAC ELISA), the sensitivity of the test was 87.01 % with 100 % specificity. The positive and negative predictive values (PPV and NPV) were 100 % and 94.47 %, respectively. In precision testing, standard deviation (SD) and coefficient of variation (% CV) values of the C-MAb ELISA were within acceptable limits. The C-MAb ELISA detected anti-CHIKV IgM in serum of patients up to five months after the onset of infection, indicating that anti-C MAbs have strong potential for use in MAC ELISA to detect recent CHIKV infection.

show abstract

Expression of the capsid protein of Chikungunya virus in a baculovirus for serodiagnosis of Chikungunya disease

Cited by 21 publications

References 29 publications

Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein

Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein

Laboratory diagnosis of chikungunya virus: Do we really need it?

Diagnostic potential of monoclonal antibodies against the capsid protein of chikungunya virus for detection of recent infection

Contact Info

Product

Resources

About